Can a Lung Transplant Cure Pulmonary Fibrosis?

A lung transplant does not cure pulmonary fibrosis in the way an antibiotic cures an infection, because it does not eliminate the underlying disease process. What it does is replace scarred, failing lungs with functioning donor lungs, which can dramatically extend life and restore the ability to breathe independently. For many people with advanced pulmonary fibrosis, transplant is the only intervention that meaningfully changes the trajectory of the disease. But the distinction between “cure” and “life-extending treatment” matters here more than it does for almost any other organ transplant, and understanding why requires looking at what happens both before and long after surgery.

What Pulmonary Fibrosis Does to the Lungs

Pulmonary fibrosis is the end result of a group of diseases in which normal lung tissue is progressively replaced by scar tissue. In the most common and aggressive form, idiopathic pulmonary fibrosis (IPF), the tiny air sacs responsible for getting oxygen into the blood are destroyed as scar tissue builds up in and around them.¹ The lungs become stiff, gas exchange deteriorates, and over time the person needs supplemental oxygen just to get through routine activities. Without intervention, this process leads to respiratory failure and death.²

The scarring process is driven by a cascade of events that begins with repeated injury to the cells lining the air sacs. In people who develop IPF, the repair mechanism goes haywire. Instead of healing normally, injured cells send signals that activate fibroblasts, the cells that produce scar tissue, and those fibroblasts keep working long after the original injury has passed.³ Genetic predisposition, aging, environmental exposures, and immune system quirks all feed into this cycle. The important thing for transplant discussions is that these triggers live in the person’s body, not just in the lungs. Replacing the lungs removes the scarred tissue but does not switch off whatever started the scarring in the first place.

When Transplant Gets Discussed

Doctors do not wait until someone is on the edge of death to bring up transplant. International guidelines recommend referring patients to a transplant program at the time a definite or probable pattern of usual interstitial pneumonia (the hallmark of IPF) is identified on imaging, or when lung function has dropped below certain thresholds, or when oxygen is needed at rest or during exercise.⁴ For people with inflammatory forms of interstitial lung disease, the recommendation is referral when the disease keeps progressing despite maximum medical therapy.

These referral criteria are deliberately early. Being referred does not mean being listed for transplant tomorrow; it means beginning evaluation at a center so that if and when the disease worsens, the team is already familiar with the patient’s case. IPF is unpredictable. Some people remain stable for years, while others decline rapidly. Patients who arrive at a transplant center already in crisis have worse outcomes, partly because there is less time to optimize their condition and partly because the sickest patients carry the highest surgical risk. Research into better prediction tools is active. One recent study developed a classifier combining clinical variables and blood proteins that could identify patients heading toward near-term decline with roughly 70 percent sensitivity and up to 92 percent specificity, though this kind of tool is still being validated.⁵

Antifibrotic Drugs Before Transplant

Two medications, pirfenidone and nintedanib, can slow the rate at which lung function declines in IPF. Neither stops fibrosis entirely or reverses existing scarring, but they buy time. A practical question many patients and doctors face is whether to keep taking these drugs right up until surgery, given that they affect blood vessel growth and wound healing. The evidence is reassuring. Multiple studies have found that continuing antifibrotic therapy until the moment of transplant does not increase rates of surgical bleeding, airway complications, or poor wound healing.⁶

One study went further, finding that patients who had been on antifibrotic agents actually had lower rates of early graft dysfunction after surgery compared to those who had not, along with lower 90-day mortality.⁷ The current standard of care is to continue these medications right up to the day of transplant.⁶ For patients waiting on the list, nintedanib has also been shown to slow lung function decline during that waiting period, which helps keep them in good enough shape to survive surgery.⁸

Single Lung or Both

Whether to replace one lung or both has been debated for decades. Single-lung transplant is a shorter, less complex operation, which matters for older or frailer patients. Bilateral transplant gives better post-operative lung function. In studies comparing the two approaches for IPF, people who received two lungs could walk farther and had better breathing test results afterward.⁹

The survival question is trickier. A large analysis using the U.S. organ allocation system found that bilateral transplant was associated with better graft survival for IPF patients, with an adjusted median survival of about 65 months compared to roughly 50 months for single-lung recipients.¹⁰ However, a meta-analysis looking at overall survival found no statistically significant difference when all studies were pooled together, though single-lung recipients had higher rates of death from malignancy over time while bilateral recipients had higher rates of early graft dysfunction deaths.¹¹ In practice, the choice depends on the patient’s age, overall health, and whether a suitable pair of donor lungs is available. The trend has been toward bilateral transplant when feasible, but single-lung transplant remains a reasonable option for many.

How Long Do Transplant Recipients Live

Survival after lung transplant for pulmonary fibrosis has been improving. A study tracking outcomes across two time periods found that one-year survival improved from around 80 percent in 2005 to approximately 90 percent by 2020, and five-year survival rose from about 52 percent in the earlier era to roughly 55 percent in the later one.¹² Those numbers reflect averages across all patients, including those transplanted in emergency situations. For people who reach transplant in reasonably stable condition, outcomes tend to be better. A separate analysis of single-lung transplant recipients with pulmonary fibrosis reported survival of 83 percent at one year, 59 percent at five years, and 29 percent at ten years.¹³

These survival rates are meaningful for a disease that, without transplant, has a median survival of only about three to five years after diagnosis. But they also underscore why “cure” is the wrong word. Roughly half of IPF transplant recipients do not survive to five years, and the reasons for that reveal the limits of organ replacement as a strategy.

Why It Is Not a Cure

The most fundamental reason a transplant cannot cure pulmonary fibrosis is that it trades one set of serious medical problems for another. The new lungs require lifelong immunosuppressive drugs to prevent rejection, and those drugs carry their own heavy burden. A study tracking long-term complications in transplant recipients found that kidney failure developed in about 57 percent, osteoporosis in 55 percent, high blood pressure in 45 percent, and diabetes in roughly 20 percent.¹⁴ The suppressed immune system also leaves patients vulnerable to infections and increases their risk of certain cancers over time.

Then there is chronic lung allograft dysfunction, the umbrella term for what happens when the transplanted lung gradually stops working properly. CLAD is predominantly driven by chronic rejection and is the leading cause of death beyond the first year after transplant.¹⁵ In its most common form, the airways of the transplanted lung become inflamed and scarred, slowly choking off airflow. This process, somewhat ironically, is itself a form of fibrosis, though of a different type and location than the original disease.

Can Fibrosis Come Back in the New Lungs

Disease recurrence in a transplanted lung is rare, complicating fewer than one percent of all lung transplants. But it does happen. Case reports have documented fibrosis reappearing in transplanted lungs months after surgery, with biopsies showing the same pattern of disease that destroyed the original lungs.¹⁶ In at least one documented case, the recurrence was traced to recipient immune cells (macrophages) that migrated into the donor lung and began accumulating abnormally within two months of the transplant, eventually triggering the same fibrotic process all over again. This supports the idea that the driver of disease lives in the recipient’s biology, not in the lungs themselves.

A recent review described disease recurrence as “a significant concern” in the field and emphasized the need to better understand which patients are at risk so that recipient selection and monitoring can improve.¹⁷ For most recipients, recurrence of the original fibrosis pattern is not what limits their lifespan. Chronic rejection and the complications of immunosuppression are far more common threats. But the possibility of recurrence is another reason the word “cure” does not fit.

When the Fibrosis Has a Genetic Root

An increasingly recognized subset of pulmonary fibrosis patients carry mutations in genes related to telomere maintenance. Telomeres are the protective caps on the ends of chromosomes, and when they are abnormally short, cells throughout the body age and fail prematurely. People with these telomere-related forms of fibrosis may develop lung scarring at younger ages, and they often have problems in other organs as well, including the bone marrow and liver.

For these patients, lung transplant poses extra challenges. Their short telomeres make them more sensitive to the immunosuppressive drugs used after transplant, leading to higher rates of low blood cell counts, more frequent viral infections like cytomegalovirus reactivation, and more airway complications.¹⁸ A systematic review found that overall survival after transplant in telomere-related fibrosis did not appear clearly worse than in other forms, but the specific complication profile was different enough to warrant careful genetic counseling and tailored immunosuppression.¹⁹ Identifying telomere mutations before transplant matters because it changes how the post-transplant medication regimen is managed.

Fibrosis Caused by Connective Tissue Disease

Not all pulmonary fibrosis is idiopathic. Autoimmune conditions like rheumatoid arthritis, scleroderma, and inflammatory myositis can attack the lungs and produce scarring that looks and behaves much like IPF. For people with connective tissue disease-related fibrosis (CTD-ILD), transplant introduces another layer of complexity: the autoimmune disease does not go away when the lungs are replaced.

Overall, transplant outcomes for CTD-ILD are broadly similar to those for IPF. Rates of allograft failure and all-cause mortality are comparable between the two groups.²⁰ But there is a significant exception: patients with myositis-related fibrosis had roughly five times higher three-year mortality compared to IPF recipients, along with increased rates of blood clots, digital ischemia, and infection. Early graft dysfunction rates were also similar between CTD-ILD and IPF, though patients with connective tissue disease tended to stay in the hospital longer after surgery.²¹ For this population, the ongoing systemic disease adds complications that a lung-only intervention cannot address.

Quality of Life After Transplant

If transplant does not cure pulmonary fibrosis, what does it actually accomplish? For many recipients, the gains in daily functioning are enormous. Studies consistently find dramatic improvements in health-related quality of life after lung transplant, particularly in measures of physical health and the ability to perform everyday activities.²² One study using a lung-transplant-specific quality-of-life scale found that scores improved by nearly two standard deviations after surgery, a very large effect.²³ People go from being unable to cross a room without oxygen to walking, traveling, and in some cases returning to work.

Physical rehabilitation plays a role in maximizing these early improvements. Psychological conditions and the eventual development of chronic rejection can erode quality of life over time, but for most recipients, the first several years after transplant represent a period of function that would have been impossible otherwise. Whether that trade is worth the risks of surgery, lifelong immunosuppression, and ongoing medical monitoring is an intensely personal decision, but for people who are otherwise heading toward respiratory failure, the calculus usually favors transplant.

Bridging to Transplant When the Lungs Are Failing Now

Some patients deteriorate faster than donor lungs become available. For those in acute respiratory failure while on the waiting list, extracorporeal membrane oxygenation (ECMO), a machine that oxygenates blood outside the body, can serve as a bridge. One case report described a 40-year-old man with interstitial lung disease who was placed on ECMO, extubated within two hours, and was then able to eat, drink, and exercise while awaiting a donor. He successfully underwent transplant 18 days later.²⁴ A larger database analysis confirmed that ECMO bridging is effective even in IPF patients with severe pulmonary hypertension, a complication that makes both the waiting period and the surgery itself more dangerous.²⁵

Another technology expanding the donor pool is ex vivo lung perfusion, or EVLP, which allows transplant teams to take marginal donor lungs, those that would previously have been rejected, and rehabilitate them in a machine. Early clinical data showed that lungs treated this way actually had a tendency toward lower rates of graft dysfunction compared to conventionally accepted donor lungs.²⁶ For a disease where waiting-list mortality is a real problem, technologies that either keep patients alive longer or increase the supply of usable organs make a tangible difference.

Who Gets Access

A lung transplant can only help if you can get one, and access is far from equal. In the United States, the lung allocation score (LAS) prioritizes organs based on medical urgency and expected benefit, and IPF patients generally score high because of the disease’s poor natural trajectory. But higher allocation scores at the time of transplant are also associated with worse post-transplant survival, reflecting the fact that the sickest patients carry the greatest surgical risk.²⁷

Beyond medical urgency, socioeconomic factors play a striking role. An analysis of a large IPF registry found that higher neighborhood income was strongly associated with receiving a transplant, independent of disease severity. Each $10,000 increase in median zip-code income raised the likelihood of transplant by about 22 percent, while having no effect on the likelihood of death, meaning sicker patients in lower-income areas were just as likely to die but far less likely to receive a transplant. Being enrolled at a center that had a transplant program increased the chance of transplant more than fourfold.²⁸ Geography and money, in other words, shape who gets a transplant as much as biology does.

Research Beyond Transplant

Given the limitations of organ replacement, researchers are looking for treatments that might actually reverse fibrosis or regenerate damaged lung tissue. Stem cell therapy is the most actively explored alternative. A large body of preclinical work has shown that various types of stem cells can reduce fibrosis in animal models, partly by dampening inflammation and partly by releasing signals that encourage healthy tissue repair.²⁹ Human trials are in early stages, and no stem cell therapy is currently approved for pulmonary fibrosis.

Further out on the horizon is the concept of bioartificial lungs, using natural or synthetic scaffolds seeded with living cells to create functional lung tissue that could be transplanted without the need for a human donor.³⁰ The lung is one of the most architecturally complex organs in the body, so this remains a distant goal. But the field is motivated by the same gap that makes the “cure” question so loaded: transplant works, but it is not enough, not available enough, and not durable enough to be the final answer for pulmonary fibrosis.